To what extent the host defense role of granule-associated antibacterial proteins and peptides of PMN includes extracellular action has not been established. To Invest. 1995Invest. . 95:1916Invest. -1924
Introduction
The passage of PMN from the circulation into inflammatory sites is a complex process that is initiated by interactions between PMN and endothelial cells and that is accompanied by heightened functional activity of the PMN (1) (2) (3) (4) . Among nu-merous responses to signals that prompt PMN to translocate, the cells increase surface expression of various receptors ( 1, 3) and may release portions of the contents of their storage granules (2, 5). The extracellular release by PMN in an inflammatory exudate of granule constituents is viewed as secretion by a viable cell rather than by a disintegrating PMN (2) . What biological role the released material serves in inflammation is not clear. The extracellular release by PMN of proteinases such as elastase and collagenase may facilitate transendothelial migration of PMN but is also considered a major factor in the genesis of joint damage in inflammatory joint disease (2, 6, 7) . Other secreted PMN products exhibit monocyte-specific chemotactic activity in vitro (8) (9) (10) and may promote influx of these cells later in the inflammatory response. Since the PMN granules contain an array of antimicrobial agents (10) (11) (12) (13) , we have considered the possibility that their release into the extracellular environment might add to the antimicrobial potential of an inflammatory exudate. To this end we took advantage of a long-standing animal model of inflammation (14), namely, a sterile peritoneal exudate induced in rabbits by intraperitoneal injection of glycogen in physiological saline. We found that, during the course of the development of the exudate, the cellfree (ascitic) fluid (AF)' gains potent antibacterial activity directed against both Gram-negative and Gram-positive bacteria. The activity toward a Gram-negative serum-resistant encapsulated Escherichia coli strain is largely attributable to two PMNderived antimicrobial proteins, the bactericidal/permeability-increasing protein (BPI) and a 15-kD protein (pl5). This report concerns the identification, quantitation, and antimicrobial activities of these proteins in ascitic fluid.
Methods
Bacteria. Bacteria used in this study included E. coli J5, a rough UDPgalactose-4-epimeraseless mutant of the smooth strain 0111 :B4 (15) , E. coli Ki /r and 07K1 ( grown either in nutrient broth containing 0.9% (wt/vol) saline (E. coli J5) or in trypticase soy broth (other bacteria). Stationary phase over-night cultures were transferred to fresh medium (diluted 1:100) and grown to late logarithmic phase (-4 h) at 370C. Bacterial concentrations were determined by measuring the OD5M in a spectrophotometer.
Subcultures were harvested by sedimentation of bacteria at 3,000 g for 12 min. Bacteria were resuspended in sterile physiological saline to the desired concentration.
Collection ofAF and PMNfrom inflammatory peritoneal exudates. Sterile inflammatory peritoneal exudates were elicited in New Zealand white rabbits (2-3 kg) by intraperitoneal injection of 250-300 ml of sterile physiological saline supplemented with oyster glycogen (2.5 mg/ ml). At various times (4-24 h) after injection, the inflammatory exudate was collected from the peritoneal cavity via a 16-gauge needle. The cell concentration of the exudate was measured by counting an aliquot in a hemocytometer. The cells were collected by sedimentation (100-200 g for 5 min), and the cell differential was determined after staining a smear of the cells with a leukostat stain kit (Fisher Diagnostics, Pittsburgh, PA). Cell pellets were stored at -20oC before use. The inflammatory AF was collected by sedimentation of the cells in the exudate followed by centrifugation of the recovered supernatant at 20,000 g for 10 min to remove particulate material before storage at 40C. To normalize protein concentrations, AFs collected at earlier times were concentrated up to 10-fold by ultrafiltration (Centricon-10 concentrator; Amicon Corp., Danvers, MA) without loss of antibacterial activity.
Collection ofplasma and PMNfrom blood. Rabbit peripheral blood was collected from the marginal ear vein both just before and 16 h after intraperitoneal inoculation of glycogen/saline. Blood was collected into a tube containing buffered citrate as anticoagulant. Plasma was isolated by sedimentation of blood cells by centrifugation at 2,500 g for 10 min. To control for the possible effect of citrate on antibacterial activity, AF was assayed without added buffer or with citrate or phosphate buffer, pH 7.4. PMN were enriched by sedimentation of erythrocytes in citrated blood in 1% (wt/vol) dextran T-500 at 1 g and by centrifugation of the leukocyte-rich upper phase. Residual erythrocytes were lysed by resuspension of the cells in isotonic ammonium chloride as described in reference 17. Cell concentration and the proportion of PMN ( 2 70% PMN) were determined as described above.
Fractionation ofAF or plasma by CM-Sephadex chromatography. AF or plasma was incubated with rotation for 1 h at room temperature with CM-Sephadex (100 jil resin/ml of AF or plasma) (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ). Before use, the resin was prepared according to the directions of the manufacturer, equilibrated in 0.9% (wt/vol) saline buffered with 2.5 mM Tris-HCl, pH 7.5, and spun to remove excess solution. Unbound proteins were recovered in the supernatant after sedimentation of the resin by centrifugation at 1,000 g for 30 s. The resin was washed twice with gel equilibration buffer (each wash equaled the original volume of AF or plasma). Bound proteins were eluted by washing the resin twice with 0.1 vol of 1.5 M NaCl containing 20 Fig. 4 , incubation mixtures contained 90% (vol/vol) buffered (buffered citrate or 10 mM sodium phosphate, pH 7.4) AF or plasma and 10% (vol/vol) physiological saline containing a final concentration of 106 bacteria/ml, and the incubations were carried out for up to 60 min at 370C. At the end of the incubation, aliquots of the suspensions were taken and serially diluted in sterile physiological saline. A 25-iul aliquot of the diluted sample was transferred to 5 ml of molten (480C) 1.3% (wt/vol) Bactoagar (Difco Laboratories Inc., Detroit, MI) containing either 0.8% (wt/vol) nutrient broth and 0.5% (wt/vol) NaCl (for plating of E. coli) or 3% (wt/vol) trypticase soy broth (for plating of staphylococci). The agar was allowed to solidify at room temperature, and bacterial viability was measured as the number of colonies formed after incubation at 370C for 18-24 h.
Neutralization of antibacterial activity of AF or plasma by goat anti-BPI serum. Buffered AF and plasma, either undiluted or diluted in the typical incubation medium, were preincubated with 3% (vol/vol) goat serum (normal or anti-BPI) for 15 min at room temperature before addition of bacteria (in 10 Al) and continuation of incubation for up to 60 min at 370C. Bacterial viability was then measured as described above. Neutralizing effects of this antiserum on BPI-mediated antibacterial activity were previously described ( 16) . Preparation of PMN lysates for Western blots. Cell pellets were resuspended in lysis buffer (1% Triton X-100, 1% deoxycholate, and 1 mM PMSF) at 108 PMN/ml and sonicated for 2 min in a water bath sonicator (40 W; 4°C). After incubation on ice for 1 h, an equal volume of 2X SDS sample buffer was added, and the samples were boiled until no turbidity was visible. Samples representing 2.5 and 5 x 104 PMN equivalents were applied to SDS polyacrylamide gels.
Immunodetection of BPI. Protein samples were resolved by SDS-PAGE in 10% polyacrylamide gels and transferred to 0.2 ism nitrocellulose (Schleicher & Schuell, Inc., Keene, NH) at 200 mA for 16 h (18). The blots were blocked by incubation for 1 h at room temperature with 0.3% BSA buffered with TBS (10 mM Tris-HCI, pH 7.4, in 0.9% NaCl) containing 0.1% sodium azide, washed with TBS for 5 min, and then exposed to 0.1% (vol/vol) goat anti-BPI serum in 0.3% BSA/TBS/ 0.1% sodium azide/0.5% NP-40/SmM EDTA, pH 8.0 (incubation buffer), at room temperature for 3 h. Blots were washed six times with TBS and once with incubation buffer (5 min each). Bound antibody was detected by incubation for 3 h in incubation buffer supplemented with 0.2% (vol/vol) l25I-protein G (-4 x 105 cpm/ml; Amersham Corp., Arlington Heights, IL). After six 5-min washes with TBS, blots were exposed for autoradiography on XAR film (Eastman Kodak Co., Rochester, NY). To distinguish between BPI and a structurally related plasma-derived LPS-binding protein (LBP; 19), duplicate samples were resolved in gradient Phast Gels (10-15% polyacrylamide; Pharmacia LKB Biotechnology, Inc.) and reacted after transfer with either 0.1% (vol/vol) goat anti-BPI serum or anti-LBP serum.
Immunodetection of plSs. Analyses were carried out in the same way as described above for BPI except that samples were resolved in 14% polyacrylamide gels, and 0.3% (vol/vol) guinea pig anti-plS serum was used.
For quantitation of BPI and p1Ss in experimental samples, all blots also contained known amounts of purified BPI or p15 (25-400 ng). Measurement of protein bands in autoradiograms was carried out using the Optical Imaging System (Ambis Systems Inc., San Diego, CA). Miscellaneous. Protein concentrations were determined by A280/260
and by protein assay (Bio-Rad Laboratories, Richmond, CA) as described by the manufacturer, using serum albumin as standard.
Results
Potent antibacterial activity of rabbit AF toward both serumsensitive and -resistant E. coli. Cell-free AF collected 16 h after intraperitoneal injection into rabbits of 250 ml of sterile physiological saline supplemented with oyster glycogen (2.5 mg/ml) possesses potent antibacterial activity against both serum-sensitive E. coli (J5) and serum-resistant encapsulated E.
coli (Kl /r) (Fig. 1) . The activity of AF toward E. coli J5 was greater than or equal to that of plasma (or serum, not shown). The activity of AF toward E. coli Ki /r far exceeded that of plasma (or of serum; not shown) collected either before or 16 h after inoculation (Fig. 1) . Thus, this activity in AF is not simply a result of exudation of plasma constituent(s) but rather appears to be due to component(s) released locally into AF.
The antibacterial activity of AF was highly consistent, not only in samples collected from a single rabbit over a period of several months but also in samples obtained from different rabbits (Fig. 2) . There was no reduction in activity during storage of AF at 40C for up to 6 mo.
The total (Fig. 3 A) and specific antibacterial activity/ml of AF (toward E. coli K1/r) (Fig. 3 B) increased with time up to 24 and 12 h, respectively, after injection of the glycogen solution, further indicating that the antibacterial activity is attributable to component(s) of AF that accumulate at a rate different from that of the bulk protein (mainly plasma albumin). However, the increase in antibacterial activity did parallel the influx of PMN into the peritoneal exudate, suggesting that products released from PMN may be the source of antibacterial activity in AF.
Effect of anti-BPI serum on antibacterial activity of AF toward encapsulated E. coli. The most potent major protein product of PMN known to be toxic toward encapsulated E. coli is BPI (11, 16, 20) . We therefore tested the effect of neutralizing BPI antibodies on the antibacterial activity of AF. Fig. 4 A shows that anti-BPI serum virtually abolished the antibacterial activity of AF toward E. coli K1i/r, whereas addition of similar amounts of normal serum had no effect. These effects were seen over the entire dose range of AF tested, suggesting that all antibacterial activity of AF toward E. coli K1/r was dependent on BPI. The same results were obtained with each of several AFs tested. At high concentrations (90% vol/vol), plasma had a modest bactericidal effect during longer incubations (. 30 min) that was also (partially) inhibited by anti-BPI serum (Fig. 4 B) .
Strains of E. coli producing long-chain (smooth chemotype) LPS are more resistant to BPI (11, 15) and also to AF (data not shown). However, at high concentrations (90% vol/vol of 16-and 24-h exudates), AF but not plasma or serum produced complete inhibition of the viability of up to 106 E. coli 07K1 / ml (Fig. 4, C and D) . The E. coli 07K1 was also completely inhibited by anti-BPI serum (Fig. 4 C) . BPI-independent antibacterial activity ofAF toward staphylococci. AF (but not plasma) also caused killing of Grampositive bacteria, including S. aureus (Fig. 4 , E and F) and S. epidermidis (data not shown). BPI alone is nontoxic to Grampositive bacteria (11, 21) . Killing of the staphylococci by AF was not inhibited by anti-BPI serum, confirming that these effects of AF were not BPI-dependent. Thus, in contrast to plasma (or serum), AF contains potent broad-spectrum antimicrobial activity, some of which appears to be dependent on BPI.
Partial purification by ion-exchange chromatography ofantibacterial activity ofAF toward encapsulated E. coli. To rial activity toward E. coli KI /r was recovered in the unbound (buffered physiological saline wash, pH 7.4) fraction (Fig. 5  A) . In contrast, the fraction adsorbed to CM-Sephadex and eluted with acetate (pH 4.0)-buffered 1.5 M NaCl ("high salt eluate") contained < 0.5% of the total AF protein but -50% of the total antibacterial activity. The activity of this bound protein fraction was unaffected by recombining with the unbound proteins recovered from AF or from plasma (Fig. 5 A) . The distribution of antibacterial activity in AF from different animals and collected at 4, 12, and 24 h after inoculation was essentially the same. Antibacterial activity toward E. coli Ki /r was not unmasked by fractionation of plasma (Fig. 5 B) , sug-S. aureus (Fig. 7) .
These findings strongly suggest that the antibacterial activity of AF reflects the combined actions of BPI and the pl~s.
Unlike BPI, the p15 content in AF could be measured directly by immunoblots of whole AF (Fig. 8 B) . This BPI (ng) Figure 7 . Antibacterial activity toward E. coli Kl/r of AF is reconstituted by purified BPI and plSs. The BPI and p15 content of AF (rabbit #1) was measured as described in Methods. BPI and plSs were purified from PMN of the same rabbit (24) and added in amounts corresponding to that present in AF. Effects on viability of E. coli Kl /r were measured as described in Methods and in the legend to Fig. 1 . The results shown represent the mean of two closely similar experiments.
Time course of accumulation of BPI and the pi5s in AF. The cellular and extracellular (plasma and AF) contents of BPI and pl5s in peripheral blood and peritoneal exudates were measured using the same quantitative immunodetection methods. The BPI and p15 content of AF increased with time of collection (Table I) in parallel with the increase in antibacterial activity toward E. coli K1 /r (see Fig. 3 ). In contrast, the amount of BPI and p5 in PMN, derived either from blood or from the peritoneal exudate, was essentially the same at all times collected. At maximum, -10% of the total p15 content in the inflammatory exudate (cells + fluid) and < 2% of BPI was recovered in the AF.
Comparison ofBPI and p15 contents of 16-h AFs collected from different animals. Table II shows that the higher antibacterial activity of AF collected from rabbit No. 1, in comparison to AF from rabbits Nos. 3 and 4 (see Fig. 2 ), also paralleled the higher BPI and p15 content of the AF of this animal. In contrast, the total protein concentration in AF from rabbit No. 1, the PMN concentration in the exudates from this animal, and the BPI and p15 content in the PMN of rabbit No. 1 were not significantly different from those of the other animals.
This study demonstrates potent and increasing antibacterial activity toward serum-resistant encapsulated E. coli in the AF of an evolving sterile inflammatory exudate induced by injection of glycogen into the peritoneal cavity of the rabbit. The accumulation of antibacterial activity parallels the increase in the concentration of PMN in the exudate and is of comparable magnitude from rabbit to rabbit and on repeated challenge. As early as 4 h after injection of glycogen, antibacterial activity of the AF is readily detectable and continues to increase during the next 8-20 h. In contrast, the plasma does not gain antimicrobial activity after the local inflammatory challenge. Antibacterial activity is stable during storage of AF for months at 40C, indicating that this activity is largely attributable to biologically stable agents. The fact that neutralizing antibodies against BPI can abolish virtually all antibacterial effects of AF toward E. coli Kl/r and 07K1 implies that BPI is an essential element in the antimicrobial activity of AF against these organisms. However, by itself, the BPI concentration in AF accounts for c 20% of the observed antibacterial activity (Fig. 7) . We have recently shown that other PMN granule proteins, the plSs, and the most potent rabbit defensins (NP-1, 2) can act synergistically with BPI, reducing the dose of BPI required for growth inhibition as much as 50-fold when subinhibitory doses of the plSs and/or NP-1 (2) are also present (24) (25) (26) . The AF contains substantial amounts of the plSs (up to 2 pM; Table II ). These concentrations of the pl5s alone do not affect growth of E. coli Kl/r but, together with BPI (10-20 nM) , in the amounts present in AF, display essentially the same growth-inhibitory potency toward E. coli K1/r as the whole AF. Thus, BPI + piSs can account for nearly all the growth-inhibitory activity of the AF toward E. coli KI/r. NP-1 and -2 are also present in the AF (Weinrauch, Y., and J. Weiss, unpublished observations). However, in contrast to BPI and the pl5s, the bulk of the defensins are not recovered in native form but as slow migrating species during acid-urea PAGE, probably reflecting high molecular weight complexes with a2-macroglobulin or C1 (27, 28) . These complexes are apparently devoid of antimicrobial activity.
At the concentrations of albumin present in AF, the antibacterial effects of purified BPI±pl5 do not rapidly progress from reversible, sublethal alterations to actual killing (24, 26, 29) . In contrast, the whole AF in most instances produces rapidly lethal effects (Weinrauch, Y., and J. Weiss, Although our experiments have focused mainly on the antibacterial activity of AF toward E. coli, it is apparent that this inflammatory fluid possesses potent, broad-spectrum antimicrobial activity, including antistaphylococcal activity (see Fig. 4 ). This BPI-independent activity is not present in plasma and therefore may also reflect the secretion of antimicrobial (poly)-peptides by PMN ( 18, 25, 34) . Our measurements of the cellular The extent to which the mRNA detected in these cells is translated and contributes to the accumulation of PMN proteins in the AF is under study. Whatever the mechanism(s) of the accumulation of such proteins in AF, this study demonstrates for the first time the extracellular mobilization of sufficient endogenous BPI to account for prominent extracellular BPI-like antibacterial activity. This is the first time that an antibacterial role in a natural environment has been documented for any of the PMN-derived oxygen-independent antimicrobial proteins or peptides. Recently, others have also observed elevated extracellular levels of BPI in plasma of septic patients and volunteers after LPS administration and, to an even greater extent (as in our study), in AF collected from patients on chronic peritoneal dialysis, especially when infected (38-40). However, no biological activity of extracellular BPI was assessed in these studies. It should be emphasized that the potency of BPI in AF reflects not only the amount of BPI in this fluid and the intrinsic potency of BPI but also its ability to act synergistically with another secreted PMN protein, p15.
Lastly, it should be noted that BPI (and the plSs) possess potent LPS (endotoxin) -neutralizing activity (20, (41) (42) (43) (44) . It has been speculated previously that release of BPI from PMN at inflammatory sites could provide a feedback mechanism to turn off the inflammatory response provoked by invading Gramnegative bacteria (43, 45) . It should be noted that levels of LBP, a homologue of BPI that is an important positive regulator of endotoxin activity (19) , are far lower in inflammatory fluid than in plasma (Fig. 6 B; 40) . Thus, in inflammatory fluids, extracellular BPI and pl5s may not only exert their antibacterial (cytotoxic) action but may also downregulate further inflammatory reactions triggered by bacteria or their constituents (LPS). In contrast to analyses of occasional clinical samples, this highly reproducible rabbit model of (acute) inflammation should permit the detailed study of the evolution of the inflammatory response and its regulation by the mobilization and integration of cellular and extracellular host defenses.
